DH
Diana Hausman
Director

Diana Hausman insider trades: Immuneering (IMRX) stock buys and sales

Director, Immuneering Last trade Jul 2, 2025 25 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
8
Open-market trades
since 2015
4
Companies
last trade 2025

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Diana reports to the SEC

Open-market buys and sales

8 trades reported on SEC Form 4, newest first

DateStockTypeValue
Jul 2, 2025IMRX↑ Buy$11K
Jul 2, 2025IMRX↑ Buy$9K
May 9, 2024ZNTL↓ Sell$42K
Mar 10, 2021ZYME↓ Sell$37K
Dec 4, 2020ZYME↓ Sell$332K
Dec 2, 2020ZYME↓ Sell$1.0M
Sep 14, 2020ZYME↓ Sell$1.8M
Jun 1, 2015ONTY↑ Buy$27K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other IMRX insiders

Open-market trades in the last 12 months

About Diana Hausman's insider trades

Diana Hausman is a director at Immuneering (IMRX). Since Jun 1, 2015, Diana has reported 3 open-market purchases worth $47K and 5 sales worth $3.3M on SEC Form 4. There have been no open-market trades in the last 12 months.

Their filings also include grants and awards (19 filings), option exercises (4 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every IMRX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.